

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 5/19/1953
Gender: Male
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 01/01/2017 12:34

Bullous Pemphigoid Antigens (180 kDa and 230 kDa), IgG

ARUP test code 0092566

Bullous Pemphigoid Antigens, IgG

See Note

IMMUNODERMATOLOGY REPORT

Specimen(s):
1. Hemolyzed serum specimen

Clinical/Diagnostic Information:
No clinical information provided.

DIAGNOSTIC INTERPRETATION

Normal IgG Bullous Pemphigoid Antigens, BP 180 and IgG BP 230, antibody levels by ELISAs

(See Results and Comments including with attention to the interpretation relating to hemolyzed serum specimen and additional test recommendations)

RESULTS

Enzyme Linked Immunosorbent Assay (ELISA)

Bullous Pemphigoid (BP) 180 and 230 IgG Antibodies

IgG BP 180 antibodies: 2 units

Reference Range:
Positive (H) = Greater than or equal to 9 units
Negative = Less than 9 units

IgG BP 230 antibodies: 1 unit

Reference Range:
Positive (H) = Greater than or equal to 9 units
Negative = Less than 9 units

(H = high/increased; units = units/mL serum)

COMMENTS
Specific

This specimen showed visible evidence of hemolysis upon receipt in the Immunodermatology Laboratory which could be associated with anomalous test results. Interpretation of the findings should take this potential into consideration with retesting of a non-hemolyzed serum specimen if the findings do not correspond to the clinical presentation and as recommended.

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

Patients with pemphigoid may show reactivity to multiple basement membrane zone components other than the BP 180 and BP 230 epitopes expressed in these ELISAs; therefore, these normal results do not rule out a diagnosis of pemphigoid. These results also do not rule out treated or evolving pemphigoid or other immunobullous diseases. Clinical correlation is needed including with direct immunofluorescence on a biopsy specimen and treatment status.

Serum testing for IgG and IgA basement membrane zone antibodies by indirect immunofluorescence or, more broadly, for IgG and IgA basement membrane zone and cell surface antibodies by indirect immunofluorescence and additional ELISAs can provide further immunopathological/diagnostic information. To further evaluate the immunopathological profile in this patient's serum, repeat and additional testing with a newly submitted, non-hemolyzed serum specimen is recommended, including for:

Basement membrane zone antibody-associated diseases (pemphigoid and pemphigoid variants, epidermolysis bullosa acquisita, and linear IgA disease including linear IgA bullous dermatosis) with

- IgG Epithelial Basement Membrane Zone Antibody (ARUP test number 0092056) and
- IgA Epithelial Basement Membrane Zone Antibody (ARUP test number 0092057) and
- IgG Collagen Type VII antibodies by ELISA (ARUP test number 2010905)

or

Basement membrane zone and cell surface antibody-associated diseases (pemphigoid and pemphigoid variants, epidermolysis bullosa acquisita, linear IgA disease including linear IgA bullous dermatosis, and pemphigus and pemphigus variants) with

- Epithelial Skin Antibody Panel (ARUP test number 0090299) and
- IgG Desmoglein 1 and IgG Desmoglein 3 Antibodies (ARUP test number 0090649) and/or
- IgG Collagen Type VII antibodies by ELISA (ARUP test number 2010905).

Detection, patterns, and levels of diagnostic antibodies may fluctuate with disease manifestations. Monitoring antibody profiles by indirect immunofluorescence as well as antibody levels by ELISAs may aid in assessing disease expression and activity.

General

Major molecular structures in the basement membrane zone to which IgG pemphigoid antibodies bind have been identified and termed "BP180" for a 180 kDa bullous pemphigoid antigen and "BP 230" for a 230 kDa bullous pemphigoid antigen. BP 180 is a transmembrane component of the basement membrane zone with collagen-like domains. BP 230 is located in the hemidesmosomal plaque of basal cells in the epidermis. Serum levels of IgG BP 180 and IgG BP 230 antibodies are in the negative range in normal individuals, and serum levels of IgG BP 180 antibodies correlate with disease activity in some patients with pemphigoid, diminishing in response to therapy.

TESTING METHODS

Enzyme Linked Immunosorbent Assay (ELISA)

IgG BP 180 and IgG BP 230 serum antibody levels determined by U.S. Food and Drug Administration-approved ELISAs (Mesacup, MBL BION).

[Two ELISAs]

██████████, MD

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 19-144-402244
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 2 of 3 | Printed: 12/16/2020 8:10:08 AM
4848

Immunodermatologist
Electronically signed 5/31/2019 5:40:12AM
Performed at: ARUP - University Hospital Laboratory 50 N.
Medical Drive Salt Lake City UT 84132

EER Bullous Pemphigoid Antigens, IgG

See Note

Access ARUP Enhanced Report using the link below:

-Direct access:

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Bullous Pemphigoid Antigens, IgG	19-144-402244	5/22/2019 9:38:00 AM	5/28/2019 8:08:36 AM	5/31/2019 3:24:00 PM
EER Bullous Pemphigoid Antigens, IgG	19-144-402244	5/22/2019 9:38:00 AM	5/28/2019 8:08:36 AM	5/31/2019 3:24:00 PM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at: